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Background: The mechanisms by which stress hormones impact triple-negative breast cancer (TNBC) etiology and treatment are
unclear. We have previously shown that stress hormones, cortisol, and catecholamines induce rapid DNA damage and impact
DNA repair in NIH 3T3 fibroblasts. This study investigates whether stress hormones increase DNA damage in breast cancer cells
and if this impacts drug efficacy.
Methods: We first screened a panel of 39 breast cancer cell lines for expression of adrenergic and glucocorticoid receptors and
examined if stress hormones induce DNA damage and alter cell cycle regulation in vitro. A TNBC xenograft model was used to
assess the impact of restraint stress on tumour growth and chemosensitivity to paclitaxel.
Results: We found that stress hormones induced DNA damage, phosphorylation of ATR, which was accompanied by an up-
regulation of the G1 cell kinase inhibitor p21 and a cell cycle halt of TNBCs in the G1 phase. p21 knockdown abrogated G1 arrest
by stress hormones. We also demonstrated that stress significantly decreased efficacy of paclitaxel.
Conclusion:We describe a novel mechanism through which stress hormones can induce drug resistance to paclitaxel, which may
have profound implications for treating drug resistance in patients with TNBC.
Triple-negative breast cancer (TNBC) accounts forB15–20% of all
subtypes of breast cancer and are characterised by a lack of
expression of estrogen/progesterone and ERBB2 (Ossovskaya et al,
2011; Metzger-Filho et al, 2012). Patients with TNBC are treated
with standard chemotherapy treatments and these patients exhibit
shorter disease-free survival and a high rate of relapse (Dent et al,
2007; Dent et al, 2009; Brouckaert et al, 2012; Chu et al, 2012).
Furthermore, these patients with TNBC can develop resistance to
standard therapies. Although many risk factors have been
associated with the progression of breast cancer (Nelson et al,
2012), the effects of psychological stress are only now starting to be
recognised. A comprehensive meta-analysis of 165 longitudinal
studies concluded that psychosocial factors are associated with
higher incidence, poorer survival, and increased mortality from
breast cancer (Chida et al, 2008). Furthermore, exposure to stress
increases tumour growth and metastasis in animal models of breast
cancer (Hermes et al, 2009; Sloan et al, 2010; Madden et al, 2013).
However, little is known about the molecular pathways by which
stress-induced hormones may influence development and progres-
sion of breast cancer tissues that possess stress hormone receptors
(Vazquez et al, 2006b), although there are several possibilities
(Flint and Bovbjerg, 2012). The b-adrenergic receptor is arguably
the most well-studied receptor in the context of catecholamine-
induced tumour progression (Thaker et al, 2006; Sloan et al, 2010;
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Sood et al, 2010). However, the role of catecholamines in drug
resistance has not been well established. Glucocorticoids, such as
dexamethasone, have been reported to have a role in drug
resistance in breast cancer by enhancing anti-apoptosis mechan-
isms and transcriptional regulation of genes regulating cell-survival
mechanisms (Wu et al, 2004; Petrella et al, 2006). In addition,
patients with ER-negative tumours expressing high levels of GR
had a worse prognosis (Pan et al, 2011). Further work by the same
group showed that pre-treatment with the GR receptor blocker,
mifepristone, actually enhanced the efficacy of paclitaxel through
increases in anti-apoptotic mechanisms in TNBC (Volden and
Conzen, 2013; Skor et al, 2013a, b).
We previously showed that stress hormones (cortisol, (Cort),
norepinephrine (NE), and epinephrine (E)) at physiological
concentrations rapidly induce DNA damage, and interfere with
the DNA-damage repair process in pre-cancerous cells leading to
cell transformation and tumorigenicity (Flint et al, 2007; Flint et al,
2012). Consistent with our initial findings, although not in cancer
cells, two recent reports suggest molecular mechanisms by which
catecholamines can trigger DNA damage and suppress p53 levels,
respectively, thus synergistically leading to the accumulation of
elevated levels of DNA damage (Hara et al, 2011, 2012). We have
shown that stress hormones not only induce rapid DNA damage,
but also impact DNA repair by altering DNA repair proteins such
as Chk1 and Chk2 kinases (Flint et al, 2007). We have previously
shown in vitro using MDA-MB-231 breast cancer cells that stress
hormones can negatively affect the efficacy of a microtubule
disrupting agent, paclitaxel, in co-culture through Cdk-1 (Flint
et al, 2009). However, the direct impact of stress hormones on
cancer cells to render them drug resistant is not yet known. In this
manuscript, we test our hypothesis that stress hormones can
induce drug resistance in TNBC models by confirming the
presence and function of stress hormone receptors, assessing
DNA damage and cell cycle arrest by stress hormones and test the
effects of restraint stress on the efficacy of paclitaxel in a mouse
model.
MATERIALS AND METHODS
Cell lines. Breast cancer cell lines were purchased from American
Type Culture Collection and obtained from the Integrative Cancer
Biology Program (ICBP) 45 breast cancer cell line kit (ICBP45) of
the National Cancer Institute. MDA-MB-231 cells were cultured in
Dulbecco’s Modified Eagle’s Medium and Hams nutrient mixture
(F-12) and HCC1187 cells were cultured in RPMI-1640 and F-12
1 : 1 each with 4mM L-glutamine and charcoal-stripped bovine calf
serum (10%) and MCF-7 Cells were cultured in DMEM and
charcoal-stripped bovine calf serum (10%) in a 37 1C incubator at
5% CO2. All cells were plated in a six-well plate and experiments
performed in triplicate unless indicated otherwise.
Hormone and chemotherapy studies. Cortisol, norepinephrine,
RU486, propranolol, and paclitaxel (Sigma, St Louis, MO, USA)
were prepared as described previously (Flint et al, 2009). Breast
cancer cells were incubated with paclitaxel (10 7 M) and either
cortisol (10 6 M) or NE (10 7 M) individually, or in combination.
These concentrations mimic the physiological levels of circulating
cortisol and NE generated during acute stress reported by other
researchers (Rupprecht et al, 1997; Rupprecht et al, 1999). To
determine hormone specificity, cells were co-treated with the GC
receptor antagonist, RU-486 (10 6 M) or beta-adrenergic receptor
antagonist, propranolol (10 6 M) for 30min before stress
hormones.
QPCR method for adrenergic receptor screening for breast
cancer cell lines. Total RNA extraction was performed using GE
Healthcare (Piscataway, NJ, USA) illustra RNAspin Mini RNA
Isolation Kit protocol. Total RNA quantified by Nanodrop 2000
spectrophotometer. Total RNA (1mg) was used for first strand
synthesis reaction using Bio-Rad (Hercules, CA, USA) iScript
Reverse Transcription Supermix according to manufacturer
protocol. SYBR Green PCR Mastermix (Applied Biosystems,
Foster City, CA, USA) was used and the cDNA was analysed on
Bio-Rad C1000 Thermal Cycler CFX96 Real-Time System, and
CFX Software. Data were analysed with the Standard Curve
Method using beta-actin as an internal reference gene. Primers:
Integrated DNA Technologies custom designed intron- spanning
codes for mRNA: eight adrenergic receptors, glucocorticoid
receptor, and beta-actin (Table 1).
cAMP assay. Intracellular cAMP content was measured using an
Enzyme Immune Assay kit (Cayman-Cyclic AMP EIA kit; Ann
Arbor, MI, USA) according to the manufacturer’s protocol. MDA-
MB-231 cells were incubated with indicated concentrations of NE
or 1 mM forskolin for various times. After treatment, the cells were
incubated with 0.1 M HCl before incubation with cAMP tracers
overnight, developed with Ellman’s reagent and analysed at 405 nM
Table 1. Primer sequences
NR3C1 NM_000176.2 NR3C1_mRNAþ CCCGTTGGTTCCGAAAATTG
NR3C1_mRNA- AGCTTACATCTGGTCTCATGC
ADRA1A NM_000680.2 ADRA1A_mRNAþ ACTTCTCAGTGAGGCTCCT
ADRA1A_mRNA- AGGGCTTGAAATCAGGGAAG
ADRA1B NM_000679.3 ADRA1B_mRNAþ GCATTGTGGTCGGTATGTTC
ADRA1B_mRNA- TGAGGCAGCTGTTGAAGTAG
ADRA1D NM_000678.3 ADRA1D_mRNAþ AGAAAGCGGCCAAGACTC
ADRA1D_mRNA- AAGATGACCTTGAAGACGCC
ADRA2A NM_000681.3 ADRA2A_mRNAþ GTCATGGGCTACTGGTACTTC
ADRA2A_mRNA- TTCAGGTTGTACTCGATGGC
ADRA2B NM_000682.5 ADRA2B_mRNAþ CTGCCCTTCCCAACTCAG
ADRA2B_mRNA- CCTCTTCAGCTTCATCCTCTG
ADRA2C NM_000683.3 ADRA2C_mRNAþ CTTCTGGATCGGCTACTGC
ADRA2C_mRNA- AGAGGATGTGCTTAAAGGATCG
ADRB1 NM_000684.2 ADRB1_mRNAþ CTGCTACAACGACCCCAAG
ADRB1_mRNA- TAGAAGGAGACTACGGACGAG
ADRB2 NM_000024.5 ADRB2_mRNAþ TCTTCACGAACCAAGCCTATG
ADRB2_mRNA- AGACCCTGGAGTAGACGAAG
BRITISH JOURNAL OF CANCER Stress hormones reduce the efficacy of paclitaxel
1462 www.bjcancer.com |DOI:10.1038/bjc.2015.133
using a Luminometer (Promega Glomax Multidection system,
Sunnydale, CA, USA).
Dual luciferase assay. Cells were plated in a 24-well plate for 24 h
before transfection with an expression plasmid coding for a GR VS
fusion protein, a reporter plasmid containing the luciferase gene
linked to a synthetic promoter containing TAT3 binding sites and
a Renilla expression plasmid (Fugene 6, Promega, Madison, WI,
USA). Cells were stimulated with NE in media containing 10%
charcoal-stripped FBS for 16 h. Both luciferase and Renilla activity
were quantified with the Dual-Glo Luciferase Assay System
(Promega) using a luminometer (Wallac Victor3, PerkinElmer
Biosciences, Waltham, MA, USA). Luciferase activity was normal-
ised to the Renilla activity within each sample.
Comet assay. TNBC cells were embedded in LMAgarose in
preparation for the Comet assay a single-cell gel electrophoresis
assay (Collins, 2004). A total of 1 105 cells were mixed in low
melting point agarose in PBS and pipetted onto slides pre-coated
with 1% agarose and the comet was performed exactly as described
previously (Flint et al, 2007).
Cell cycle analysis. Cells were treated with paclitaxel and stress
hormones as described above. Briefly, cells were trypsinised,
washed with PBS and fixed with 100% ethanol at 4 1C for 1 h. Cell
suspensions were then incubated with 50 ng ml 1 of RNase A for
15min at 37 1C followed by 50 ng ml 1 of propidium iodide for
30min at 4 1C in the dark. Cells were analysed on a LSR II flow
cytometer using the FACSDiva data analysis software (BD
Biosciences, San Jose, CA, USA). Cell cycle distributions were
generated using BD FACS Diva software version 6.1.1.
Immunofluorescence. Cells were plated into six-well plates on
coverslips before exposure to stress hormones for 4 h. Cells were
fixed with 4% paraformaldehyde at RT for 15min and washed with
PBS. Cells were permeabilised with 0.25% Triton X-100 for 10min,
washed with PBS, and blocked with PBS, 0.1% Tween-20, and 1%
BSA for 30min. Cells were incubated with an anti-phospho-H2AX
primary antibody (Cell Signaling, Beverley, CA, USA) for 2 h,
followed by an anti-Rabbit Alexa 546 (Molecular Probes by Life
Technology, Grand Island, NY, USA) for 1 h. Cells were washed
with PBS and counterstained with 0.1 mgml 1 Hoechst stain and
mounted to glass slides with Prolong Gold antifade reagent
(Molecular Probes, Life Technology). One hundred cells were
scored at random for each sample using an epi-fluorescence
microscope described earlier. All experiments were performed in
duplicate.
Gene silencing with siRNAs. For gene silencing, RNAi siRNA
against p21 was purchased from Cell Signaling. Control siRNA
(Cell Signaling) was used as a negative control. Transient
transfection of siRNA was carried out using Lipofectamine reagent
(Invitrogen, Paisley, UK) according to the manufacturer’s instruc-
tions. Two 105 cells were plated into six-well plates 24 h before
transfection. Cells were incubated with the final concentration
(20 nM) of siRNA for control and p21 with Lipofectamine for 48 h
followed by 24 h exposure of stress hormones. Cells were
subsequently processed for either flow cytometry or western blot
(see below).
Western blot. Following treatments with stress hormones, cells
were trypsinised, washed with PBS, and lysed with 50mM Tris, pH
7.5, 150mM NaCl, 10mM NaF, 1mM NaVO4, 10mM sodium
pyrophosphate, 1% Triton X-100. Lysates were cleared at 13 000 g
for 10min. Protein concentration was measured using the
Bradford Protein Assay (Bio-Rad). A total 30mg of protein was
eluted in reducing SDS–PAGE sample buffer (Bio-Rad) and
resolved by SDS–PAGE, then transferred onto nitrocellulose
membranes. Blots were blocked with 5% BSA in 0.1% TBS-T
followed by probing with the following primary antibodies p21;
Cell Signaling, Phospho-ATR (Ser428), ATR Phospho-Chk1
(Ser345) (133D3) Rabbit mAb, (DNA Damage Antibody Sampler
Kit #9947), ATR, Cell Signaling (2390) Rabbit mAb, Chk-1 goat
mAB (Abcam AB2845, Cambridge, MA, USA), Cell Signaling and
phospho histone gH2AX; Millipore, Temecula, CA, USA), and
then incubated with corresponding HRP-conjugated secondary
antibodies. Mouse anti-actin (Millipore) primary antibody served
as a control. Protein quantification was conducted by densito-
metric analysis using Image J software.
Cell viability. Cell viability was assessed using a standard trypan
blue assay (Sigma). Cells were treated with stress hormones as
described above. Cells were treated with 1mM of paclitaxel or
vincristine in the presence or absence of stress hormones.
Xenografts. Female nude mice (nu/nu; 6 weeks old; 20±2 g) were
used. The animal room was maintained on a 12-h light/12-h dark
diurnal cycle. All animals were given food and water ad libitum. All
mouse protocols were approved by IACUC at the University of
Pittsburgh. Mice were injected with 5 106 MDA-MB-231 cells
per 0.2ml) into the left inguinal mammary fat pad. The tumours
took 6–8 weeks to become established, with tumour volumes
B80–100mm3. Tumour volumes were calculated twice weekly
using a digital caliper and the formula, vol (mm3)¼ LxW2/2;
length (L, mm) and width (W, mm). Mice bearing xenografts were
randomised 3 days before treatment (day  3). At day 0, groups of
mice received either a dose of paclitaxel (IP; dose of 10mg kg 1
per week for 3 weeks) or vehicle (Cremophor EL-ethanol-saline
1 : 1 : 8 (v/v/v) as 0.01ml g 1 body weight on day 0, 7, and 14. For
the stress model, (described in (Flint et al, 2000, 2011) groups of
mice were placed individually in adequately ventilated tubes.
Restraint stress was applied to test groups (chemotherapy and
vehicle-treated groups) three times a week (1000–1200 hours) for 3
weeks. Mice were removed from the study if tumours exceeded
2000mm3.
Statistical analyses. Measurements from cell culture assays were
compared between groups against control or against the pre-
determined reference group using analysis of variance. Tumour
volume measurements were log-transformed to satisfy linearity
assumptions and a mixed model was fit to account for correlation
of repeated measures within subject. Growth rates, represented as
slopes, were compared across and within groups. Within-group
means and standard deviations are reported and all tests are two-
sided at a nominal 0.05 significance level.
RESULTS
Stress hormone receptors are dynamically expressed in breast
cancer cell lines. We observed that different breast cancer cell
lines with diverse pathological and molecular features exhibited
heterogeneity in expression levels of stress hormone receptors GR
and each ADR (Figure 1A). Further analyses showed that GR
expression is significantly higher in TNBC cell lines (P¼ 0.01,
Figure 1B). ADRB2 expression (one of the key catecholamine
receptors in cancer) was also found to trend higher in a subset of
TNBC (Supplementary Figure S1A). We used MDA-MB-231 cells;
a widely used model of TNBC with previously reported stress
hormone receptors (Vazquez et al, 2006a) and HCC1187 cells; a
TNBC model expressing higher levels of ADR and GR, for further
analyses. Both cells lines are basal and possess p53 mutations. We
showed that GR was constitutively expressed in MDA-MB-231
cells and was increased by the synthetic GC, dexamethasone
P¼ 0.001 (Figure 1C). NE increases cAMP production through a-
or b-ADR and we found that NE increased cAMP levels in MDA-
MB-231 cells in a dose-dependent manner (Figure 1D). To fully
evaluate that a mechanism through which stress hormones could
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induce drug resistance, we initially tested whether NE can
stimulate the GR (Schmidt et al, 2001) and we determined that
although GR was constitutively expressed in both TNBC cells
and increased by dexamethasone, NE had no significant effect
on GR expression in MDA-MB-231 cells but decreased GR
expression in the presence of DEX in HCC1187 cells
(Supplementary Figure S1B and C).
Stress hormones induce DNA damage and cause G1 arrest. In
MDA-MB-231 cells, treatment with Cort and NE induced a
significant two-fold increase in DNA damage (P¼ 0.01 for each
hormone; Figure 2A). Similarly, in HCC1187 cells, which express
relatively high levels of GR and ADR, we observed a three-fold
increase in DNA damage by Cort and NE (Po0.001 for each
hormone) (Figure 2B). When exposed to the hormones in
combination, DNA damage was greater than with treatment of
Cort or NE alone in MDA-MB-231 cells (P¼ 0.0001 compared
with control and P¼ 0.03 compared with Cort or NE only)
suggesting an additive effect and HCC1187 (P¼ 0.0001 compared
with control). An additive effect in HCC1187 cells was not
observed although this may be because the damage observed was at
the highest detection limit for the assay. Hydrogen peroxide-
treated cells served as a positive control. To determine whether
cells lines expressing wild-type p53 are also prone to DNA damage
by SH, we conducted the same experiment in MCF-7 breast cancer
cell lines and we found that similar to TNBC, we observed a
significant increase in DNA damage Po0.001 for each hormone
(Supplementary Figure S2)
In MDA-MB-231 cells, we found that Cort and NE increased
gH2AX phosphorylation when compared with unstimulated
controls at 24 h. Lower concentrations of NE increased gH2AX-P
with the peak response at 10 6 M Cort and 10 7 M NE, whereas
a high concentration (10 5 M) partially decreased gH2AX-P
(Supplementary Figure S3). Further, NE and Cort (Po0.001 for
both) induced prominent gH2AX foci in MDA-MB-231 cells and
increased gH2AX by NE (P¼ 0.02) and Cort (P¼ 0.06) in
HCC1187 cells (Figure 2C and quantification Figure 2D and E).
Treatment with 10 mM cisplatin for 24 h served as a positive control
and induced a marked increase in the number of cells expressing
gH2AX foci (Figure 2C). We also observed a significantly
diminished presence of nuclei in cells treated with receptor
antagonists, RU-486 and propranolol before exposure to corre-
sponding stress hormones Cort and NE.
FACS analyses showed that a higher percentage of MDA-MB-
231 cells were found in the G1 phase following treatment with
stress hormones (P¼ 0.04, Figure 3A). A higher fraction of cells
treated with paclitaxel alone were found in G2/M phase
(P¼ 0.003). Combined treatment of paclitaxel and stress hormones
resulted in a significant proportion of cells remaining in G1,
compared to paclitaxel alone (P¼ 0.003 in MDA-MB-231),
presumably preventing paclitaxel from targeting the cells in the
G2/M phase of the cell cycle. Interestingly, we did not observe a
striking G1 arrest when receptor antagonist were added for each
hormone. Alternatively, we used BT474 cells, which have low
expression of SH receptors (Figure 1A) and although others have
shown GR expression in BT474 cells, they did not exhibit G1 cell
cycle arrest in response to DEX (Sumikawa et al, 2008); further, we
found that NE failed to induce cAMP in cells and stress hormones
did not result in significant cell cycle arrest in G1 phase of the cell
cycle (Figure 3B and C), suggesting that stress hormone effects on
the cell cycle are receptor mediated; however, further work
dissecting these the role of the glucocorticoid and adrenergic
receptors in G1 cell cycle halt is warranted.
Stress hormones induce ATR, Chk1 phosphorylation and p21
expression through GR and ADR. Similar to gH2AX P levels, we
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observed a dose response for phosphorylated ATR and p21 with
the peak response at 10 6 M Cort and 10 7 M NE, while the high
concentration (10 5 M) partially decreased phosphorylated levels
of ATR and p21 (Supplementary Figure S3). MDA-MB-231 cells
were treated with stress hormones for 2 and 6 h and western
blotting for phospho-ATR, phospho-Chk1, and p21 was performed
(Figure 4A, quantifications B–D). At 2 h, we found that NE and
Cort individually and more robustly in combination increased
ATR serine 425 phosphorylation and total protein levels were
slightly decreased at 2 h. Although this did not achieve statistical
significance, we found that stress hormones increased Chk1 serine
345 phosphorylation (a major target of ATR) in two out of three
experiments, which was inhibited when cells were pretreated with
propranolol and RU-486 (mifepristone). Chk1 total protein
expression was increased in all treatments at 2 and 6 h. At 6 h,
ATR phosphorylation was not sustained, and total ATR protein
levels remained unchanged, demonstrating that the DNA damage
response is working effectively. We initially determined that
paclitaxel, NE, and Cort increased p21 at 2, 6, and 24 h with the
most robust increases at 2–6 h (Supplementary Figure S4). We
further confirmed this data at 2 and 6 h and showed that Cort and
NE showed a trend towards an increase in p21, and these levels
were reduced in cells pre-treated with RU-486 and propranolol,
respectively. The most striking finding was that treatment with a
combination of Cort and NE significantly increased p21 at both
time points (Figure 4A).
Similar to MDA-MB-231 cells, in HCC1187 cells, we observed
an increase in ATR with NE and Cort at 2 h, which was reversed in
cells pretreated with the receptor antagonist, propranolol
(Supplementary Figure S5). We observed increases in phospho-
Chk1 with Cort but not with NE at 2 h and p21 was increased in
cells treated with NE and Cort alone at 2 h and Cort at 6 h
(Supplementary Figure S5). Because the hormones were shown to
arrest cells in the G1 phase, this would serve as a mechanism to
inhibit paclitaxel efficacy, which targets cells in the G2/M phase.
To confirm the role of p21, we used two approaches; p21
knockdown in our MDA-MB-231 cells and MDA-MB-436 cells,
which have been reported to possess little or no p21 (Promkan
et al, 2009). Using the first approach, we found that SH induced G1
arrest in cells treated with control siRNA and significantly
prevented in cells treated with p21 siRNA (Figure 5A and western
blot showing knockdown Figure 5B). In MDA-MB-436 cells, we
found that treatment with stress hormones had no effect on the
efficacy of paclitaxel as evidenced by a lack of significant changes in
G1 cell cycle arrest and cell viability (Figure 5C and D).
Furthermore, Phospho-ATR and Chk1 were not increased by
stress hormones compared with unstimulated cells (Figure 5E).
Stress hormones prevent microtubule targeting agent-induced
cell cytotoxicity. MDA-MB-231 cells were incubated with pacli-
taxel (Pac; a microtubule stabilising agent) or Vincristine (Vin;
inhibitor of microtubule assembly) in the presence or absence of
Cort NE and E for 24 h (Figure 6A and B). At 24 h, Pac killed 50%
of the cells (P¼ 0.003 compared with unstimulated) and that this
mortality was decreased by treatment with Cort or NE individually
and significantly decreased in combination (P¼ 0.03) at 24 h.
Similarly at 24 h, Vin killed 50% of the cells and this mortality was
significantly prevented, compared with unstimulated, by co-culture
with Cort (P¼ 0.03), cat (P¼ 0.04) individually or highly
significantly in combination (P¼ 0.01).
Restraint stress decreases the efficacy of paclitaxel. To begin to
translate our findings in vivo, we designed an experiment to
establish whether psychological stress could decrease the efficacy of
paclitaxel. The stress system functions as a positive bi-directional
feedback loop; activation of one component of the system
stimulates other components at multiple levels (reviewed in
Thaker et al (2013)) we decided to use the restraint stress model
and we first wanted to ensure that our model could induce changes
in HPA axis through release of corticosterone. We determined that
mice subjected to restraint stress exhibit significantly elevated
corticosterone (the cortisol equivalent in mice). We found that
mice stressed for 3 weeks showed an increase in corticosterone
from 48.9±34 pgml 1 to 821.4±326 pgml 1 (n¼ 5 per group;
P¼ 0.027; Figure 6C). We next showed that following a
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comparison of growth rates, paclitaxel significantly decreased
tumour volumes compared with vehicle controls (Po0.0001)
restraint stress significantly decreased the efficacy of paclitaxel
(Po0.0001) when compared with non-stressed paclitaxel-treated
controls (Figure 6D). Furthermore, stress had a significant
protective effect in vehicle-treated controls (P¼ 0.047).
DISCUSSION
We have shown that stress hormones not only induce significant
DNA damage in TNBC cell lines, but that they induce expression
of ATR and p21 in such a way as to regulate progression of the cell
cycle, an important factor in the efficacy of drug treatment. Stress
hormones were shown to arrest cells in the G0/G1 phase, which
would serve to substantiate the decrease in paclitaxel efficacy,
which targets cells in the S phase. Increasing levels of stress
hormones were also shown to induce p21 via receptor-mediated
pathways, suggesting one possible mechanism for this arrest. Two
primary signal transducers which regulate DNA damage response
pathways are ataxia telangiectasia mutated (ATM) and ATM-and
Rad3-related (ATR) kinases. The ATM and ATR kinases are
differentially activated by distinct types of DNA damage with ATR
recruited to single-strand breaks (SSBs) and ATM to double-strand
breaks (DSBs), however, ATR also responds to DSBs, and ATM
activation can induce ATR activation upon DSB induction
(Jazayeri et al, 2006). The ATR regulates Chk1 kinase and its
target CDC25 via phosphorylation, thus elevated levels of ATR and
pChk1 are indicative of the presence of DNA damage. Elevated
levels of ATR and pChk1 suggest that DNA damage recruits ATR
and subsequently regulates Chk1 kinase and its target CDC25 via
phosphorylation. This implicates that the DNA damage can
thereby prevent cell arrest and impact DNA repair. Although the
cells we used possess p53 mutations, we also observed DNA
damage in cells with wild-type p53 indicating that the effects we
observe may occur through both p53-independent and -dependent
mechanisms, further work is required to fully understand the role
of P53 (Hara et al, 2011).
Through its mediation of ATR, Chk1 and p21 via the GR and
ADR receptors, stress hormone levels possess the potential to both
increase tumorigenicity and decrease the efficacy of therapeutics,
such as paclitaxel, with microtubule stabilizing modes of action.
The role of p21 as a mediator of G1 growth arrest and as an
effector of tumour suppressor pathways such as apoptosis has
already been well established (Brugarolas et al, 1995). Glucocorti-
coids also induce cell cycle arrest and increase expression of
p21CIP1 (Rogatsky et al, 1997; Heitzer and Defranco, 2006). It has
also been shown that glucocorticoids prevent apoptosis in
chemotherapeutic-treated breast cancer cells by regulating SGK-1
and MPK-1 kinase activities (Wu et al, 2004). Our findings that a
cell line possessing little or no p21 and our p21 knockdown
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experiments highlight the importance of this molecule in relation
to stress and cell cycle halt. It could be argued that MDA-MB-436
cells have lower levels of SH receptors, which could certainly have a
part in the failure of stress hormones to induce arrest; however,
in cells treated with p21 siRNA, the reduced G1 arrest does suggest
a role of p21. Interestingly, we found that paclitaxel increased p21
when G2/M arrest was observed. Paclitaxel stabilises tubulin
polymerisation, resulting in arrest at the G2/M phase of the cell
cycle and apoptotic cell death. However, the molecular mechanism
of this growth inhibition is still poorly understood. Choi and Yu
demonstrated that paclitaxel-induced G2/M arrest and apoptosis in
MDA-MB 231 cells is mediated through p53-independent up-
regulation of p21 (Choi and Yoo, 2012). These studies indicate the
complexity of the role of P21 with paclitaxel and stress hormones.
The p21 also antithetically promotes oncogenic activity, for
example, up-regulation of p21 may actually inhibit apoptosis via
cell cycle arrest as the cell must be active to sense the
corresponding agents and induce apoptosis (reviewed in (Abbas
and Dutta, 2009)). Thus, elevation of p21 by stress hormones via
DNA damage may actually promote cell survival and migration in
TNBC; further work on this mechanism is undergoing in our
laboratory.
Our in vivo data suggest that physical restraint of tumour-
bearing mice results in a protective effect in vehicle-treated
controls and a decreased efficacy of paclitaxel. The protective effect
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of stress hormones is intriguing and that in the presence of
paclitaxel (which is a well-established inducer of apoptosis
(Saunders et al, 1997; Jeansonne et al, 2011; Miller et al, 2013))
stress can inhibit apoptosis through slowing down the cell cycle;
whereas in the absence of chemotherapy (and an inducer of
apoptosis) stress hormones have an anti-proliferative effect and the
tumours grow more slowly.
Current compelling research suggests that RU-486 used in a
neoadjuvant setting could increase tumour cell apoptosis in
chemotherapy-resistant TNBC (Skor et al, 2013a). Furthermore,
a phase II clinical trial using propranolol in addition to
chemotherapy in patients newly diagnosed with breast cancer
(NLM Identifier NCT01847001) is underway by other researchers.
Beta-blockers have also been associated with relapse-free survival
in patients with TNBC (Melhem-Bertrandt et al, 2011). However,
our data suggest that both ADR and GR have a role in drug
resistance and further mechanistic work on the use of both
propranolol and RU-486 are warranted. Collectively, these data
suggest that stress hormones affect DNA damage and cell cycle
regulation in ways that could have profound implications for the
efficacy of pharmacotherapy of breast cancer. Paclitaxel and
vincristine are unable to work efficiently in cells, which are halted
at the G1 phase of the cell cycle thereby promoting drug resistance
(Figure 7). A better understanding of the mechanism whereby
stress hormones impact drug treatments is critical to propel the
development of tailored stress-reduction interventions in patients
with breast cancer.
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